. 2014 May 1;24(4):190–200. doi: 10.1089/cap.2013.0043

Table 2.

Secondary Efficacy Measures: Efficacy Analyses Data Set^a

	Placebo n=63		Edivoxetine 0.1 n=58		Edivoxetine 0.2 n=60		Edivoxetine 0.3 n=59		OROS MPH^b n=26
	Baseline	Change at end-point	Baseline	Change at end-point	Baseline	Change at end-point	Baseline	Change at end-point	Baseline	Change at end-point
ADHD-RS-IV-Parent:Inv
Total score	38.0	−10.4	39.9	−12.2	38.1	−16.1^*	40.2	−16.4^*	40.1	−19.5^†
Inattention	20.7	−5.6	22.8	−6.2	21.8	−8.6^*	22.0	−9.1^*	21.9	−10.5^†
Hyperactivity-Impulsivity	17.3	−4.9	17.2	−5.9	16.3	−7.5^*	18.2	−7.3^*	18.3	−9.0^†
CGI-ADHD-I	−	3.1	−	3.0	−	2.5^*	−	2.5^*	−	2.3
CGI-ADHD-S	4.8	−1.1	4.8	−1.0	4.7	−1.5^*	4.9	−1.4	4.8	−1.7
CBRS
Hyperactive-Impulsive	81.1	−8.7	81.8	−6.3	80.3	−12.9	83.2	−15.7^*	79.0	−12.4
Inattentive	80.4	−10.7	81.9	−8.3	80.5	−11.0	82.6	−17.0^*	85.5	−18.3
Academic difficulty	70.3	−6.1	72.6	−6.1	71.0	−5.9	72.9	−12.5^*	74.4	−12.1
Response: CGI-ADHD-I ≤2 (%)	31.8		27.1		55.0^*		44.1		50.0
Response Rate (40% Reduction from baseline in ADHDRS-IV-Parent:Inv score)	34.9		32.8		56.7^*		47.5		53.9

^{^a}

Change scores expressed as least-squares means.

^{^b}

Patients who received OROS MPH were in the stimulant-naïve strata only.

^{^*}

p<0.05 vs. placebo; ^†p<0.05 vs. the stimulant-naïve placebo group.

0.1=0.1 mg/kg/day; 0.2=0.2 mg/kg/day; 0.3=0.3 mg/kg/day.

ADHD, attention deficit/hyperactivity disorder; ADHD-RS, ADHD rating scale; CBRS, Conners Comprehensive Behavior Rating Scales; CGI-ADHD-I, Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Improvement; CGI-ADHD-S, Clinical Global Impression-Attention-Deficit/Hyperactivity Disorder-Severity; OROS MPH, osmotic-release oral system methylphenidate.